BioWorld

March 24, 2009

Morphotek Gets SPA to Start Phase III Ovarian Cancer Trial

After yielding promising interim Phase II data, Morphotek Inc.'s farletuzumab is set to enter a pivotal, Phase III trial in ovarian cancer under a special protocol assessment. (BioWorld Today) Read More

Appeals Court Sides with Feds on GSK Patent Case

Merck Serono Launches Venture Fund with $54M Commitment

MDRNA Soars on siRNA Tech Deal with Novartis

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...